Metagenomi

Alia Therapeutics

The company develops gene editing medicines for patients with genetic diseases.

EDITAS Medicine

The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

Arbor Biotechnologies

This company develops programmable gene-editing tools and genetic medicines to treat patients with liver and central nervous system diseases.

Ensoma

This company develops in vivo genomic medicines and vector delivery platforms to engineer blood and immune cells for patients with genetic diseases and cancer.

Seamless Therapeutics

The company develops programmable recombinase-based gene editing therapies for patients with severe genetic diseases through its proprietary technology platform.

Neurogene Inc

This company develops genetic medicines and gene therapies to treat patients and families affected by rare neurological diseases including Rett syndrome and Batten disease.

Precision BioSciences

This company develops in vivo gene editing therapies for patients with genetic and infectious diseases using its proprietary ARCUS genome editing platform.